Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

52.88 -4.83 (-8.37%)

Streaming Delayed Price Updated: 11:37 AM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 ↗

May 14, 2024

These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet.

Via InvestorPlace

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 10, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma ↗

February 07, 2024

Via Benzinga

Recap: Arrowhead Pharma Q1 Earnings ↗

February 06, 2024

Via Benzinga

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 ↗

May 09, 2024

ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

May 09, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment ↗

May 02, 2024

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses...

Via Benzinga

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

May 02, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

April 29, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars

April 26, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results

April 24, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

April 24, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Turnstone Biologics Appoints William Waddill to its Board of Directors

April 16, 2024

From Turnstone Biologics Corp.

Via GlobeNewswire

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

April 07, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024 ↗

April 05, 2024

With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April.

Via InvestorPlace

NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling ↗

April 04, 2024

The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 01, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

March 25, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗

March 13, 2024

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Via InvestorPlace

The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 ↗

March 11, 2024

The Russell 2000 is up about 4% year to date, and could push higher, taking the most undervalued Russell 2000 stocks along for the ride.

Via InvestorPlace

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday ↗

March 11, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

Via Benzinga

Topics Stocks

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

March 08, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

March 04, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

7 Oversold Russell 2000 Stocks to Add to Your February Buy List ↗

February 25, 2024

Investors may want to jump into oversold Russell 2000 stocks. After a rough outing in 2023, many are starting to come back strong.

Via InvestorPlace

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 06, 2024

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

February 06, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today